emergent surgery use -- off label use | PTLA Message Board Posts

Portola Pharmaceuticals, Inc.

  PTLA website

PTLA   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  6057 of 6324  at  3/10/2019 6:30:59 PM  by

biobeware


 In response to msg 6056 by  indyengineer
view thread

Re: emergent surgery use -- off label use

 "I have mixed feelings about Europe.  A major partnering cedes some degree of ownership to the partner and reduces the buyout value of the company as a whole.  Sales ramp up in Europe is always slow as each country wants to cut its own discount deal with the company and negotiations can be protracted."

I completely understand your mixed emotions.  And I agree sales ramp in the EU can be slow and protracted due to country specific negotiations.   However, given the fact that PTLA has no infrastructure or experience in the EU, my concern is if they attempt to do it on their own it will be even slower and more protracted with parochial fumbles along the way.  That will result in patent burn and diminished buyout value.   I just think A in the US is a heavy enough lift for them and I do not see them effectively being able to handle the EU as well. 
 



     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 5     Views: 376
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board


About Us    Contact Us    Follow Us on Twitter    Members Directory    Help Center    Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
2003-2018 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...